During the past decade, Toronto Liver Center conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 8 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 7 clinical trials were completed. i.e. 140% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Toronto Liver Center" #1 sponsor was "University Health Network, Toronto" with 6 trials, followed by "Gilead Sciences" with 3 trials sponsored, "Assembly Biosciences" with 2 trials sponsored, "Arbutus Biopharma Corporation" with 1 trials sponsored and "Calliditas Therapeutics Suisse SA" with 1 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Toronto Liver Center" #1 collaborator was "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)" with 2 trials as a collaborator, "National Center for Research Resources (NCRR)" with 1 trials as a collaborator, "PRA Health Sciences" with 1 trials as a collaborator, "Pharmaceutical Research Associates" with 1 trials as a collaborator and "Triangle Biostatistics" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Toronto Liver Center" are "Hepatitis B" (7 trials), "Hepatitis C" (4 trials), "Biliary Cirrhosis, Primary" (2 trials), "Chronic Hepatitis B" (2 trials) and "Liver Cirrhosis, Biliary" (2 trials). Many other conditions were trialed in "Toronto Liver Center" in a lesser frequency.

Most popular intervention types in "Toronto Liver Center" are "Drug" (14 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Placebo to match SEL 18 mg" (2 trials), "Placebo to match SEL 6 mg" (2 trials), "SEL" (2 trials) and "AB-836" (1 trials). Other intervention names were less common.

The vast majority of trials in "Toronto Liver Center" are 22 trials for "All" genders.

Currently, there are NaN active trials in "Toronto Liver Center". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Toronto Liver Center, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Toronto Liver Center, 1 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".